A bench to bedside view of uremic toxins

Journal of the American Society of Nephrology

Volumn 19, Issue 5, 2008, Pages 863-870

  Vanholder, Raymond ^a   Baurmeister, Ulrich ^b   Brunet, Philippe ^c   Cohen, Gerald ^d   Glorieux, Griet ^a   Jankowski, Joachim ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c AIX MARSEILLE UNIVERSITY   (France)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANIDINE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN; TOXIN;

APOPTOSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME IMMUNOASSAY; HEMODIAFILTRATION; LEUKOCYTE ACTIVATION; LYMPHOCYTE HOMING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN VARIANT; RECEPTOR AFFINITY; RENAL OSTEODYSTROPHY; REVIEW; SCOTT SYNDROME; UREMIA; VASCULAR SMOOTH MUSCLE; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; RENAL REPLACEMENT THERAPY;

HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TOXINS, BIOLOGICAL; UREMIA;

EID: 44049106323     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007121377     Document Type: Review

References (80)

1. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 10: 1815-1823, 1999
2. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: Present state of the art. Int J Artif Organs 24: 695-725, 2001
3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048-1056, 2005
4. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 28: 478-483, 2007
5. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G: Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 339: 861-867, 1998
6. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? Pediatr Nephrol 2008, in press
7. Vanholder R, Van Laecke S, Glorieux G: The middle molecule hypothesis 30 years after: Lost and rediscovered in the universe of uremic toxicity? J Nephrol 2008, in press
8. Vanholder R, Hoefliger N, De Smet R, Ringoir S: Extraction of protein bound ligands from azotemic sera: Comparison of 12 deproteinization methods. Kidney Int 41: 1707-1712, 1992
9. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Horl WH: Review on uraemic toxins III: Recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrol Dial Transplant 22: 3381-3390, 2007
10. Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Drueke T, Mischak H, Spasovski G, Massy Z, Jankowski J: Review on uraemic solutes II: Variability in reported concentrations - Causes and consequences. Nephrol Dial Transplant 22: 3115-3121
11. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R: Inconsistency of reported uremic toxin concentrations. Artif Organs 31: 600-611, 2007
12. Cohen G, Rudnicki M, Walter F, Niwa T, Horl WH: Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol 12: 1264-1271, 2001
13. Vanholder R, De Smet R, Jacobs V, Van Landschoot N, Waterloos MA, Vogeleere P, Ringoir S: Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 9: 1271-1278, 1994
14. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532, 1998
15. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
16. D'Hooge R, Van de Vijver G, Van Bogaert PP, Marescau B, Vanholder R, De Deyn PP: Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 63: 1764-1775, 2003
17. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
18. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
19. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 65: 2184-2192, 2004
20. Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R: In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 66: 1873-1880, 2004
21. De Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K: Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 51: 1535-1538, 2005
22. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R: P-cresyl-sulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22: 592-596, 2007
23. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S: Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 47: 510-517, 1995
24. Au-Yeung KK, Yip JC, Siow YL, O K: Folic acid inhibits homocysteine-induced super-oxide anion production and nuclear factor kappa B activation in macrophages. Can J Physiol Pharmacol 84: 141-147, 2006
25. Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M: Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 112: 256-264, 2003
26. Jankowski J, Luftmann H, Tepel M, Leibfritz D, Zidek W, Schluter H: Characterization of dimethylguanosine, phenylethylamine, and phenylacetic acid as inhibitors of Ca2+ AT-Pase in end-stage renal failure. J Am Soc Nephrol 9: 1249-1257, 1998
27. Napoleone E, Di Santo A, Amore C, Baccante G, Di Febbo C, Porreca E, De Gaetano G, Donati MB, Lorenzet R: Leptin induces tissue factor expression in human peripheral blood mononuclear cells: A possible link between obesity and cardiovascular risk? J Thromb Haemost 5: 1462-1468, 2007
28. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340: 115-126, 1999
29. Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S: Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 5: 1581-1584, 1995
30. Passauer J, Bussemaker E, Range U, Plug M, Gross P: Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 11: 1726-1734, 2000
31. Rashid G, Benchetrit S, Fishman D, Bernheim J: Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 66: 1099-1106, 2004
32. Abahji TN, Mill L, lde N, Keller C, Hoffmann U, Weiss N: Acute hyperhomocysteinemia induces microvascular and macrovascular endothelial dysfunction. Arch Med Res 38: 411-416, 2007
33. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5: 1302-1308, 2007
34. Piccin A, Murphy WG, Smith OP: Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 21: 157-171, 2007
35. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, Brunet P, Dignat-George F: Elevation of circulating endothelial micro-particles in patients with chronic renal failure. J Thromb Haemost 4: 566-573, 2006
36. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM: Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 16: 3381-3388, 2005
37. Ramirez R, Carracedo J, Merino A, Nogueras S, Alvarez-Lara MA, Rodriguez M, Martin-Malo A, Tetta C, Aljama P: Microinflammation induces endothelial damage in hemodialysis patients: The role of convective transport. Kidney Int 72: 108-113, 2007
38. Werner N, Nickenig G: Influence of cardiovascular risk factors on endothelial progenitor cells: Limitations for therapy? Arterioscler Thromb Vasc Biol 26: 257-266, 2006
39. Urbich C, Dimmeler S: Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 95: 343-353, 2004
40. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65: 442-451, 2004
41. Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J: Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 44: 840-849, 2004
42. de Groot K, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, Fliser D: Uremia causes endothelial progenitor cell deficiency. Kidney Int 66: 641-646, 2004
43. Puri RN, Colman RW: ADP-induced platelet activation. Crit Rev Biochem Mol Biol 32: 437-502, 1997
44. Heemskerk JW, Severs EM, Lindhout T: Platelet activation and blood coagulation. Thromb Haemost 88: 186-193, 2002
45. Flodgaard H, Klenow H: Abundant amounts of diadenosine 5′,5‴-P1, P4-tetraphosphate are present, releasable, but metabolically inactive, in human platelets. Biochem J 208: 737-742, 1982
46. Luthje J, Ogilvie A: The presence of diadenosine 5′,5‴-P1, P3-triphosphate (Ap3A) in human platelets. Biochem Biophys Res Commun 115: 253-260, 1983
47. Jankowski J, Hagemann J, Yoon MS, van der Giet M, Stephan N, Zidek W, Schluter H, Tepel M: Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 59: 1134-1141, 2001
48. Jankowski J, Jankowski V, Laufer U, van der Giet M, Henning L, Tepel M, Zidek W, Schluter H: Identification and quantification of diadenosine polyphosphate concentrations in human plasma. Arterioscler Thromb Vasc Biol 23: 1231-1238, 2003
49. Steinmetz M, Janssen AK, Pelster F, Rahn KH, Schlatter E: Vasoactivity of diadenosine polyphosphates in human small mesenteric resistance arteries. J Pharmacol Exp Ther 302: 787-794, 2002
50. Jankowski V, Karadogan S, Vanholder R, Nofer JR, Herget-Rosenthal S, van der Giet M, Tolle M, Tran TN, Zidek W, Jankowski J: Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. Kidney Int 71: 994-1000, 2007
51. Jankowski J, Schluter H, Henning L, van der Giet M, Jankowski V, Zidek W, Tepel M: The AN69 hemofiltration membrane has a decreasing effect on the intracellular diadenosine pentaphosphate concentration of platelets. Kidney Blood Press Res 26: 50-54, 2003
52. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J: Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27: 297-302, 2007
53. Eloot S, Torremans A, De Smet R, Marescau B, De Wachter D, De Deyn PP, Lameire N, Verdonck P, Vanholder R: Kinetic behavior of urea is different from that of other water-soluble compounds: The case of the guanidino compounds. Kidney Int 67: 1566-1575, 2005
54. Eloot S, Torremans A, De Smet R, Marescau B, De Deyn PP, Verdonck P, Vanholder R: Complex compartmental behavior of small water-soluble uremic retention solutes: Evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis 50: 279-288, 2007
55. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002
56. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J Am Soc Neph3 rol 14: 3251-3263, 2003
57. Delmez JA, Van G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ: Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO Study. Am J Kidney Dis 47: 131-138, 2006
58. Krane V, Krieter DH, Olschewski M, Marz W, Mann JF, Ritz E, Wanner C: Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 49: 267-275, 2007
59. Locatelli F: Membrane permeability outcome: results from the MPO study. ERA-EDTA meeting, Barcelona, Spain, June 21-24, 2007
60. Locatelli F: The membrane permeability outcome (MPO) study. ASN meeting, San Francisco, CA, November 2-5, 2007
61. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Omt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 17: 546-555, 2006
62. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 69: 2087-2093, 2006
63. Jirka T, Cesare S, Di Benedetto A, Perera CM, Ponce P, Richards N, Tetta C, Vaslaky L: Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int 70: 1524-1525, 2006
64. Eloot S, Van Biesen W, Dhondt A, Van de Wynkele H, Glorieux G, Verdonck P, Vanholder R: Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008, in press; doi: 10.1038/ sj.ki.5002750
65. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40: 339-347, 2002
66. Ward RA, Greene T, Hartmann B, Samtleben W: Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 69: 1431-1437, 2006
67. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943, 2003
68. Schiffl H, Lang SM, Stratakis D, Fischer R: Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 16: 1863-1869, 2001
69. Brodersen HP, Beckers B, Clauss M, Vom DJ, Floege J, Janssen U: Identification of central venous hemodialysis catheter-related infection by a semiquantitative culture method. J Nephrol 20: 462-467, 2007
70. Vanholder R, Ringoir S, Dhondt A, Hakim R: Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. Kidney Int 39: 320-327, 1991
71. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodial-ysis. Kidney Int 53: 1399-1404, 1998
72. Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, Morgera S, Goehl H, Storr M, Boyce N, Neumayer HH: Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: A phase 1 randomized trial. Am J Kidney Dis 50: 296-304, 2007
73. Rozga J, Umehara Y, Trofimenko A, Sadahiro T, Demetriou AA: A novel plasma filtration therapy for hepatic failure: preclinical studies. Ther Apher Dial 10: 138-144, 2006
74. Sarnatskaya W, Yushko LA, Sakhno LA, Nikola ev VG, Nikolaev AV, Grinenko DV, Mikhalovsky SV: New approaches to the removal of protein-bound toxins from blood plasma of uremic patients. Artif Cells Blood Substit Immobil Biotechnol 35: 287-308, 2007
75. Abe T, Uchita K, Orita H, Kamimura M, Oda M, Hasegawa H, Kobata H, Fukunishi M, Shimazaki M, Abe T, Akizawa T, Ahmad S: Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 64: 1522-1528, 2003
76. Evenepoel P, Laleman W, Wilmer A, Claes K, Maes B, Kuypers D, Bammens B, Nevens F, Vanrenterghem Y: Detoxifying capacity and kinetics of prometheus: A new extracorporeal system for the treatment of liver failure. Blood Purif 23: 349-358, 2005
77. Calo LA, Naso A, Carraro G, Wratten ML, Pagnin E, Bertipaglia L, Rebeschini M, Davis PA, Piccoli A, Cascone C: Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 22: 1413-1419, 2007
78. Wratten ML, Sereni L, Tetta C: Hemolipodialysis attenuates oxidative stress and removes hydrophobia toxins. Artif Organs 24: 685-690, 2000
79. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Lohr M, Liebe S, Schareck W, Hopt UT, Schmidt R: Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 23: 319-330, 1999
80. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74: 349-355, 1996